Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
Zéphir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, Pittion S, Wiertlewski S, Ouallet JC, Neau JP, Ciron J, Clavelou P, Marignier R, Brassat D.
Zéphir H, et al. Among authors: ciron j.
J Neurol. 2015 Oct;262(10):2329-35. doi: 10.1007/s00415-015-7852-y. Epub 2015 Jul 21.
J Neurol. 2015.
PMID: 26194198